F-group (family)
213.1.1.4 NMT
Ligands and drugs
350
Member domains
288
with ligand contacts (≤ 4 Å)
82.3% of members
257
with DrugDomain annotations
73.4% of members
248
with a DrugBank compound
70.9% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 213.1.1.4 belongs to X-group 213 Nat/Ivy, which binds 9.0 ligand superclasses per 20 proteins, broader than 80% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB02180 | MYA | Myristoyl-Coa | 154 |
| DB08231 | MYR | Myristic acid | 18 |
| DB01992 | COA | Coenzyme A | 15 |
| DB07838 | GN8 | (Z)-3-BENZYL-5-(2-HYDROXY-3-NITROBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE | 7 |
| DB02271 | NHM | S-(2-oxo)pentadecylcoa | 4 |
| DB03062 | R64 | (1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone | 4 |
| DB02477 | MIM | N-({4-[4-(2-Methyl-1H-imidazol-1-yl)butyl]phenyl}acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide | 3 |
| DB03345 | BME | Mercaptoethanol | 3 |
| DB07061 | 3LP | 1-(CYCLOHEXYLAMINO)-3-(6-METHYL-3,4-DIHYDRO-1H-CARBAZOL-9(2H)-YL)PROPAN-2-OL | 3 |
| DB00123 | LYS | Lysine | 2 |
| DB00145 | GLY | Glycine | 2 |
| DB00174 | ASN | Asparagine | 2 |
| DB00133 | SER | Serine | 1 |
| DB03085 | GOA | Glycolic acid | 1 |
| DB03940 | OXM | Oxamic Acid | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| MYA | TETRADECANOYL-COA | 174 |
| MGmetal | MAGNESIUM ION | 123 |
| CL | CHLORIDE ION | 96 |
| NHW | 2-oxopentadecyl-CoA | 62 |
| MYR | MYRISTIC ACID | 27 |
| COA | COENZYME A | 24 |
| YNC | TETRADEC-13-YNOIC ACID - COA THIOESTER | 15 |
| 646 | 2,6-dichloro-4-(2-piperazin-1-ylpyridin-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)benzenesulfonamide | 12 |
| 9M2 | 1-[5-[4-fluoranyl-2-[2-(1,3,5-trimethylpyrazol-4-yl)ethoxy]phenyl]-2~{H}-indazol-3-yl]-~{N},~{N}-dimethyl-methanamine | 7 |
| 31A | N-[2-(3-methoxyphenyl)ethanimidoyl]-2-piperidin-4-yloxy-benzamide | 6 |
| 9K2 | 1-[5-(4-fluoranyl-2-methyl-phenyl)-1~{H}-indazol-3-yl]-~{N},~{N}-dimethyl-methanamine | 6 |
| GN8 | (Z)-3-BENZYL-5-(2-HYDROXY-3-NITROBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE | 6 |
| JCY | 1-(5-{4-fluoro-2-[2-(1,3,5-trimethyl-1H-pyrazol-4-yl)ethoxy]phenyl}-1-methyl-1H-indazol-3-yl)-N,N-dimethylmethanamine | 6 |
| KFK | 1-[5-[3,4-bis(fluoranyl)-2-[2-(1,3,5-trimethylpyrazol-4-yl)ethoxy]phenyl]-1-methyl-indazol-3-yl]-~{N},~{N}-dimethyl-methanamine | 5 |
| YN4 | ETHYL 4-[(2-CYANOETHYL)SULFANYL]-6-{[6-(PIPERAZIN-1-YL) | 4 |
| 370 | 4-[(2-{5-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]-1,3,4-oxadiazol-2-yl}-1-benzothiophen-3-yl)oxy]piperidine | 3 |
| 3F3 | 4-[(2-{5-[(3-METHOXYPHENYL)METHYL]-1,3,4-OXADIAZOL-2-YL}-1-BENZOTHIOPHEN-3-YL)OXY]PIPERIDINE | 3 |
| 4XB | 3-methoxybenzyl 3-methyl-4-(piperidin-4-yloxy)-1-benzofuran-2-carboxylate | 3 |
| 7I1 | 3-methyl-N-(naphthalen-1-ylmethyl)-4-piperidin-4-yloxy-1-benzofuran-2-carboxamide | 3 |
| 7Y6 | 4-chloranyl-N-[2-(3-methoxyphenyl)ethanimidoyl]-2-piperidin-4-yloxy-benzamide | 3 |